Targeting regulatory T cells in gastrointestinal cancers: current status and future perspectives [0.03%]
Koichi Jinushi,Takuro Saito,Yuichiro Doki
Koichi Jinushi
Although immune checkpoint inhibitors (ICIs) have revolutionized the gastrointestinal cancer treatment landscape, offering durable clinical benefits in a subset of patients, their efficacy remains limited to this subset of patients, undersc...
Survival outcomes of the patients with advanced laryngeal squamous cell carcinoma treated with chemoradiotherapy and total laryngectomy based on reports of head and neck cancer registry of Japan [0.03%]
Yuta Yamamura,Yuto Horichi,Tatsuya Furukawa et al.
Yuta Yamamura et al.
Background: Roles of induction chemotherapy (ICT) and chemoradiotherapy (CRT) for laryngeal preservation in patients with locally advanced laryngeal cancer (LC) remain unclear. ...
The fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in Chinese patients with HER2-positive early breast cancer: primary analysis of the phase III, randomized FDChina study [0.03%]
Tao Huang,Zhimin Fan,Yongsheng Wang et al.
Tao Huang et al.
Background: Neoadjuvant fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) demonstrated non-inferior cycle 7 pertuzumab and trastuzumab serum trough concentrations (Ctrough), and s...
Nationwide genomic data analysis of central nervous system tumors in Japan based on C-CAT database [0.03%]
基于C-CAT数据库的日本中枢神经系统肿瘤的全国基因组数据分析
Daisuke Kawauchi,Makoto Ohno,Masamichi Takahashi et al.
Daisuke Kawauchi et al.
Background: Comprehensive genomic profiling test (CGPT) using next-generation sequencing (NGS) plays a vital role in cancer diagnosis, treatment option, and prognostic evaluation. In Japan, three tissue-based CGPTs, Found...
Prior response to anti-VEGF agents predicts the efficacy of trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer [0.03%]
抗VEGF药物的前期反应能够预测曲氟尿苷/替匹嘧啶联合贝伐珠单抗治疗转移性结直肠癌患者的疗效
Masahiro Hirakawa,Tamotsu Sagawa,Yutaka Okagawa et al.
Masahiro Hirakawa et al.
Background: Trifluridine/Tipiracil (FTD/TPI) combined with bevacizumab (Bev) is a standard treatment for patients with unresectable metastatic colorectal cancer (mCRC) in later-line therapy. Despite the availability of ot...
Bridging the distance in precision oncology: a nationwide survey on institutional perspectives toward telemedicine and decentralized trials in Japan [0.03%]
日本全国范围内的机构对精准肿瘤学中远程医疗和分散临床试验的态度调查
Hiroya Taniguchi,Takeshi Kawakami,Hironaga Satake et al.
Hiroya Taniguchi et al.
Background: Comprehensive genomic profiling (CGP) has been reimbursed under Japan's universal health coverage since 2019, yet access remains uneven because designated institutions are concentrated in urban areas. Although...
Age-related prognostic trends in surgically resected female lymph node-metastatic gastric cancer: insights from SEER [0.03%]
美国SEER数据库女性淋巴结转移胃癌手术患者的预后特征及年龄相关性分析
Bozhi Hu,Yinli Zhang,Yingjiang Ye et al.
Bozhi Hu et al.
Background: Understanding the relationship between age and prognosis of female lymph node-metastatic gastric cancer (FLMGC) remains limited. This study aimed to elucidate the prognostic impact of age on FLMGC. ...
Association between antibiotic use, immune-related adverse events, and efficacy of immunotherapy in esophageal squamous cell carcinoma [0.03%]
抗生素使用与免疫治疗相关的自身免疫反应及疗效——食管鳞癌患者的回顾性研究
Tomoaki Shirakawa,Hiroo Imai,Ken Saijo et al.
Tomoaki Shirakawa et al.
Introduction: Immune checkpoint inhibitors (ICIs) are essential for treating esophageal squamous cell carcinoma (ESCC). As antibiotics (Abx) may reduce ICI efficacy, and immune-related adverse events (irAEs) relate to bet...
Introducing the J-CONNECT database: a real-world oncology resource for Japan [0.03%]
J-CONNECT数据库的建立：日本真实世界肿瘤学资源
Masafumi Okada,Shigemi Matsumoto,Yuriko Maehara et al.
Masafumi Okada et al.
Background: Real-world data (RWD) and real-world evidence (RWE) are increasingly important in oncology, where randomized controlled trials often exclude elderly patients, those with comorbidities, and rare cancer subtypes...
Efficacy and safety of second-line fluorouracil, leucovorin, and irinotecan plus ramucirumab according to prior first-line regimens in metastatic colorectal cancer: a multicenter retrospective study [0.03%]
不同一线方案继发转移性结直肠癌患者二线使用5-FU、亚叶酸钙和伊立替康联合ramucirumab的有效性和安全性：多中心回顾性研究
Toshinori Yanagawa,Kozo Kataoka,Hiroki Osumi et al.
Toshinori Yanagawa et al.
Background: Fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus ramucirumab is a well-established second-line treatment for metastatic colorectal cancer (mCRC) following bevacizumab-based chemotherapy. However, its ef...